The surprising failure of AstraZeneca and Ionis in a key phase 3 trial of Wainua in patients with ATTR-CM has sent the companies' shares tumbling, while those of their competitors are soaring. The CARDIO-TTRansform study did not meet its primary endpoint, which centered on reducing cardiovascular deaths or recurrent cardiovascular events through 140 weeks.
Source: FiercePharma
